The Bronchiolitis Obliterans Syndrome market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Bronchiolitis Obliterans Syndrome: An Overview
Bronchiolitis obliterans syndrome (BOS) is a form of chronic lung allograft dysfunction that affects a majority of lung transplant recipients and is the primary factor limiting long-term transplant survival. It is characterized by progressive airflow obstruction resulting in acute rejection of the graft, followed by infections, or other coexistent conditions.
Despite rapid advances in the discipline of lung transplantation and demonstrable improvement in short-term outcomes, there has been no substantial decrease in the prevalence of BOS, and no effective treatment has yet been established. This results in BOS being the principal factor contributing to limited long-term survival and suboptimal quality of life among lung allograft recipients and represents a major scientific challenge that must be surmounted before lung transplantation can become a durable, curative therapy for patients with advanced lung disease.
Bronchiolitis Obliterans Syndrome Market Key Facts
The total prevalent population of Bronchiolitis Obliterans Syndrome (BOS) in the seven major markets was 16,400+ in 2017.
Delveinsight observed a total of 6,600+ prevalent cases of Bronchiolitis Obliterans Syndrome (BOS) in the United States in 2017.
The gender-specific diagnosed prevalent cases of Bronchiolitis Obliterans Syndrome (BOS) in the United States were found to be 3,630+ males and 2,970+ females, in 2017.
Bronchiolitis Obliterans Syndrome market size is expected to increase during the forecast period owing to the increasing prevalent population of Bronchiolitis Obliterans Syndrome (BOS) patients in the 7MM, along with the expected entry of therapies such as Liposomal Cyclosporine A, Ruxolitinib, etc.
The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Bronchiolitis Obliterans Syndrome market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report gives a thorough detail of the Bronchiolitis Obliterans Syndrome market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Bronchiolitis Obliterans Syndrome Epidemiology
The epidemiology section covers insights into the historical and current Bronchiolitis Obliterans Syndrome patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Bronchiolitis Obliterans Syndrome Epidemiology Segmentation –
Total Prevalent Population
Treatable cases of BOS
Gender-Specific Diagnosed Prevalence
Grade-Specific Diagnosed Prevalence
Total Diagnosed Prevalent Population of BOS in Lung Transplant recipients
Total Diagnosed Prevalent Population of BOS in Allogenic Hematopoietic Stem cells (AHSCTs) Transplant recipients
Bronchiolitis Obliterans Syndrome Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Bronchiolitis Obliterans Syndrome market or expected to get launched in the market during the study period. The analysis covers Bronchiolitis Obliterans Syndrome market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the Bronchiolitis Obliterans Syndrome Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.
Request for Sample PDF Report – https://www.delveinsight.com/sample-request/bronchiolitis-obliterans-syndrome-market
Bronchiolitis Obliterans Syndrome Therapeutics Analysis
Key companies in the Bronchiolitis Obliterans Syndrome Market include:
And many others.
Bronchiolitis Obliterans Syndrome therapies covered in the report include:
Liposomal Cyclosporine A
And many more.
Get More Detailed Insights Into the Emerging Therapies & Key Companies – https://www.delveinsight.com/sample-request/bronchiolitis-obliterans-syndrome-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Bronchiolitis Obliterans Syndrome Competitive Intelligence Analysis
4. Bronchiolitis Obliterans Syndrome Market Overview at a Glance
5. Bronchiolitis Obliterans Syndrome Disease Background and Overview
6. Bronchiolitis Obliterans Syndrome Patient Journey
7. Bronchiolitis Obliterans Syndrome Epidemiology and Patient Population
8. Bronchiolitis Obliterans Syndrome Treatment Algorithm, Current Treatment, and Medical Practices
9. Bronchiolitis Obliterans Syndrome Unmet Needs
10. Key Endpoints of Bronchiolitis Obliterans Syndrome Treatment
11. Bronchiolitis Obliterans Syndrome Marketed Products
12. Bronchiolitis Obliterans Syndrome Emerging Therapies
13. Bronchiolitis Obliterans Syndrome Seven Major Market Analysis
14. Attribute Analysis
15. Bronchiolitis Obliterans Syndrome Market Outlook (7 major markets)
16. Bronchiolitis Obliterans Syndrome Access and Reimbursement Overview
17. KOL Views on the Bronchiolitis Obliterans Syndrome Market.
18. Bronchiolitis Obliterans Syndrome Market Drivers
19. Bronchiolitis Obliterans Syndrome Market Barriers
21. DelveInsight Capabilitie
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF Report – https://www.delveinsight.com/sample-request/bronchiolitis-obliterans-syndrome-market
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Other Latest Reports By DelveInsight
The “Injectable Drug Delivery Devices Market” is expected to reach USD 33.37 billion by 2026. Some of the key MedTech companies such Eli Lilly and Company, Biocon, Becton, Dickinson & Company, West Pharmaceutical Services, Johnson & Johnson, Antares Pharma, AbbVie, Pfizer, Mylan N.V., Vetter Pharma-Fertigung GmbH, and others are actively working in the Injectable Drug Delivery Devices Market.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States